Omeros completes $32.6mm follow-on public offering

Almost two years since its last fundraiser, Omeros Corp. (compounds for inflammation, blood loss, and neurological diseases, plus combinations of generic drugs generated by the PharmacoSurgery platform) has netted $32.6mm by publicly selling 3.4mm shares (including the overallotment) for $10.25. Proceeds will pay for clinical development of the Phase III PharmacoSurgery candidates OMS302 (ketorolac and phenylephrine) for intraocular lens replacement surgery, and OMS103HP (proprietary combination of anti-inflammatory/analgesic APIs) for reduction of pain and improvement of joint function following arthroscopic partial meniscectomy surgery. The company last completed a financing in October 2010 (one year after going public), obtaining $20mm from Vulcan Capital and affiliates in exchange for royalties on GPCR-targeting products.